Sep 29, 2010:
iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status

Sep 22, 2010:
iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board

Aug 27, 2010:
iCo Therapeutics Announces Second Quarter 2010 Financial Results

Jul 26, 2010:
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007

May 28, 2010:
iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak

May 26, 2010:
iCo Therapeutics Announces First Quarter 2010 Financial Results

May 25, 2010:
iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007

May 17, 2010:
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint

Apr 29, 2010:
iCo Therapeutics Announces Year-End 2009 Financial Results

Apr 28, 2010:
iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing

Apr 22, 2010:
iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010

Apr 12, 2010:
iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award

Feb 19, 2010:
iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials

Feb 10, 2010:
iCo Therapeutics Announces Exercise of Warrants